2875-25-4

Usage

Uses

Used in Pharmaceutical Industry:
(E)-1-(2-hydroxyphenyl)-3-pyridin-3-yl-prop-2-en-1-one is used as an active pharmaceutical ingredient for its demonstrated antibacterial, antifungal, and anti-inflammatory properties. Its multifaceted pharmacological potential makes it a promising candidate for the development of new drugs to combat various infections and inflammatory conditions.
Used in Cancer Treatment Research:
In the field of oncology, (E)-1-(2-hydroxyphenyl)-3-pyridin-3-yl-prop-2-en-1-one is used as a compound under investigation for its potential role in the treatment of cancer. Its biological activities suggest that it may have therapeutic benefits in targeting cancer cells and modulating the disease's progression.
Used in Alzheimer's Disease Research:
(E)-1-(2-hydroxyphenyl)-3-pyridin-3-yl-prop-2-en-1-one is also used as a compound in the research and development of treatments for Alzheimer's disease. Its diverse pharmacological profile indicates that it may contribute to the discovery of novel therapeutic approaches for this neurodegenerative condition.
Organic Synthesis:
(E)-1-(2-hydroxyphenyl)-3-pyridin-3-yl-prop-2-en-1-one is used as a key intermediate in organic synthesis, particularly for the creation of complex molecular structures with potential applications in various chemical and pharmaceutical processes.
Medicinal Chemistry:
In medicinal chemistry, (E)-1-(2-hydroxyphenyl)-3-pyridin-3-yl-prop-2-en-1-one serves as a valuable compound for further research and development. Its structural features and biological activities make it an attractive starting point for the design and synthesis of new drugs targeting a range of diseases and conditions.

InChI:InChI=1/C14H11NO2/c16-13-6-2-1-5-12(13)14(17)8-7-11-4-3-9-15-10-11/h1-10,16H/b8-7+

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 118-93-4 o-hydroxyacetophenone 

Downstream Products

• 3327-27-3 2-(pyridine-3-yl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Thallium(III) p-tosylate-mediated oxidative [1,2] rearrangement of 2-naphthyl and 2-heteroarylchromanones

A practical and effective approach towards the synthesis of 3-heteroaryl-4H-chromen-4-ones by the oxidative [1,2] rearrangement of the respective 2-heteroaryl chroman-4-ones using thallium(III) p-tosylate is presented. The oxidative rearrangement of α- an

Convenient synthesis of flavanone derivatives via oxa-Michael addition using catalytic amount of aqueous cesium fluoride

A total of 36 flavanones, which included polycyclic aromatic and heterocyclic rings, were readily synthesized via oxa-Michael addition from the corresponding hydroxychalcones with a catalytic amount of aqueous cesium fluoride solution under mild conditions. This method could be applied to the scalable synthesis of eriodictyol as a known potent inhibitor of the SARS-CoV-2 spike protein.

Ru, Rh and Ir metal complexes of pyridyl chalcone derivatives: Their potent antibacterial activity, comparable cytotoxicity potency and selectivity to cisplatin

Half sandwich ruthenium, rhodium and iridium complexes containing pyridyl chalcone analogues (L1 and L2) are prepared by the reaction of [(arene)M(μ-Cl)Cl]2 (arene = benzene, p-cymene, Cp*) and (M = Ru, Rh/Ir)] with L1 and L2 in 1:2 (M:L) ratio. Eight neutral mononuclear complexes (1–8) were obtained and characterized using FT-IR, 1H NMR, 13C NMR, ESI mass and UV–Vis spectroscopic methods. The molecular structures of complexes 2, 4, 5 and 7 are established by single crystal X-ray diffraction studies. Antibacterial studies were tested against three strains of bacterial microorganisms Staphylococcus aureus (gram +ve), Klebsiella pneumoniae (gram ?ve) and Escherichia coli (gram ?ve). Further the cytotoxicity study of the pyridyl chalcone derivatives and their complexes were evaluated against the human colorectal cancer cell lines HT-29, HCT-116 p53+/+, HCT-116 p53?/? and ARPE-19 (non-cancer retinal epithelium).

Compounds with NS3 serine proteinase inhibitory activity and application thereof

The invention specifically relates to compounds with NS3 serine proteinase inhibitory activity and application thereof, belonging to the field of chemical pharmacy. The invention discloses the compounds with NS3 serine proteinase inhibitory activity or pharmaceutically acceptable salts, mesomers, racemates, enantiomers, diastereomers or mixtures thereof. The structure of the compounds is as shown in the general formula (I) which is described in the specification; and the compounds comprise compounds as shown in a general formula (II) which is described in the specification, or compounds as shown in a general formula (III) which is described in the specification, or pharmaceutically acceptable salts, mesomers, racemates, enantiomers, diastereomers or mixtures thereof. Results of antiviral activity tests show that the compounds have good NS3 serine protease inhibitory activity, have the potential of being developed into novel NS3 serine protease inhibitors, and can be applied to preparation of drugs for preventing, handling and treating flavivirus infective diseases caused by hepatitis C viruses, Dengue viruses and/or West Nile viruses.

Synthesis and selective cytotoxic activities on rhabdomyosarcoma and noncancerous cells of some heterocyclic chalcones

Chemically diverse heterocyclic chalcones were prepared and evaluated for cytotoxicity, aiming to push forward potency and selectivity. They were tested against rhabdomyosarcoma (RMS) and noncancerous cell line (LLC-PK1). The influence of heteroaryl patte

Inhibitory Kinetics of Azachalcones and their Oximes on Mushroom Tyrosinase: A Facile Solid-state Synthesis

A solid-state-based mechanochemical process was used to synthesize novel azachalcones and their oximes as tyrosinase inhibitors. Their inhibitory activities on mushroom tyrosinase using l-3,4-dihydroxyphenylalanine as a substrate were investigated. Two of

Synthesis and antiviral activity of 2-aryl-4H-chromen-4-one derivatives against Chikungunya virus

A series of nineteen 2-aryl-4H-chromen-4-one derivatives 2a-2s were synthesized and evaluated for their antiviral activity against Chikungunya virus (LR2006-OPY1) in Vero cell culture by CPE reduction assay. Three compounds 2a, 2b and 2g, were found to be active at concentration of (IC50) 0.44 μM, 0.45 μM and 2.02 μM, respectively. Compounds having heterocyclic ring 2a and 2b at the 2nd position of the chromenone were found to be potent inhibitor of ChikV. Cytotoxicity studies were performed using Vero cell culture, compounds 2a and 2b exhibited SI of ≥100. Molecular docking simulation has been carried out to understand the possible mechanism of action.

Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines

Abstract A new series of thirty-six dihydroxylated 2,6-diphenyl-4-aryl pyridines containing hydroxyl groups at the ortho, meta, or para position of 2- and 6-phenyl rings attached to the central pyridine were designed and synthesized. They were evaluated f

Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones

A series of twenty 2-aryl-4H-chromen-4-one (flavones) derivatives (3a-3s) were synthesized and tested for hMAO inhibitory activity. Fifteen compounds (3a, 3c, 3e-3h, 3j-3p, 3r, 3s) were found to be selective towards MAO-B, while 3d was selective towards MAO-A, and 3b, 3i and 3q were non-selective. Experimental Selectivity Index for MAO-B ranges from 2.0 (3g, 3p) to 30.0 (3j). Compound 3j, which is carrying 3,4-di-OMeC6H3 groups at R position on the molecule, was found to be potent MAO-B inhibitor amongst the fifteen with Ki value for MAO-B of 0.16 ± 0.01 lM comparable to that of standard drug, Selegiline (Ki for MAO-B is 0.16 ± 0.01 μM). Compound 3j also appeared as the most selective MAO-B inhibitor according to its best selectivity index (30.0), which is comparable to that of Selegiline (SIMAO-B = 35.0). Molecular docking and molecular dynamics simulation studies were carried out using Autodock-4.0 and Amber12 to understand the molecular level interaction and energy relation of MAO isoforms with selective inhibitors (3d and 3j). Simulation results are in good agreement with the experimental results. Leads identified may further be explored to develop potent isoform specific inhibitors of MAO.

Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones

A series of twenty 2-aryl-4H-chromen-4-one (flavones) derivatives (3a-3s) were synthesized and tested for hMAO inhibitory activity. Fifteen compounds (3a, 3c, 3e-3h, 3j-3p, 3r, 3s) were found to be selective towards MAO-B, while 3d was selective towards MAO-A, and 3b, 3i and 3q were non-selective. Experimental Selectivity Index for MAO-B ranges from 2.0 (3g, 3p) to 30.0 (3j). Compound 3j, which is carrying 3,4-di-OMeC6H3 groups at R position on the molecule, was found to be potent MAO-B inhibitor amongst the fifteen with Ki value for MAO-B of 0.16 ± 0.01 μM comparable to that of standard drug, Selegiline (Ki for MAO-B is 0.16 ± 0.01 μM). Compound 3j also appeared as the most selective MAO-B inhibitor according to its best selectivity index (30.0), which is comparable to that of Selegiline (SIMAO-B = 35.0). Molecular docking and molecular dynamics simulation studies were carried out using Autodock-4.0 and Amber12 to understand the molecular level interaction and energy relation of MAO isoforms with selective inhibitors (3d and 3j). Simulation results are in good agreement with the experimental results. Leads identified may further be explored to develop potent isoform specific inhibitors of MAO.